These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27483355)

  • 1. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
    Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
    Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
    Ogawa Y; Nonaka Y; Goto T; Ohnishi E; Hiramatsu T; Kii I; Yoshida M; Ikura T; Onogi H; Shibuya H; Hosoya T; Ito N; Hagiwara M
    Nat Commun; 2010 Oct; 1():86. PubMed ID: 20981014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
    Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
    Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
    Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
    Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.
    Choi M; Kim AK; Ham Y; Lee JY; Kim D; Yang A; Jo MJ; Yoon E; Heo JN; Han SB; Ki MH; Lee KS; Cho S
    Phytomedicine; 2021 Nov; 92():153695. PubMed ID: 34500300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
    Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH
    J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
    Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
    Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
    Chaves JCS; Machado FT; Almeida MF; Bacovsky TB; Ferrari MFR
    Neurosci Lett; 2020 Jan; 714():134541. PubMed ID: 31605772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
    Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
    PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.